Loading company…
Volastra Therapeutics develops treatments for cancers associated with chromosomal instability.
Founded in 2019 and based in New York, US, Volastra Therapeutics develops treatments for metastatic and chromosomally unstable cancers. Its pipeline includes VLS-1488, a KIF18A inhibitor. Lewis Cantley, Olivier Elemento, and Samuel Bakhoum founded the company, led by CEO Charles Hugh-Jones as of 2023. In March 2023, it raised USD 60 million in Series A funding co-led by ARCH Venture Partners, Polaris Partners, and Eli Lilly & Company, with Catalio Capital Management, DROIA Ventures, and Vida Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in